Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhiping Fan

Showing results (121-130 of 152) with videos related to

Pageof 16
Sort By:
Journal of Translational Medicine|May 28, 2025
Efficacy and safety of third-generation CD19-CAR T cells incorporating CD28 and TLR2 intracellular domains for B-cell malignancies with central nervous system involvement: results of a pivotal trialBailin He, Ren Lin, Na Xu, et al.
Leukemia|November 18, 2020
A new pre-emptive TKIs strategy for preventing relapse based on BCR/ABL monitoring for Ph+ALL undergoing allo-HCT: a prospective clinical cohort studyHui Liu, Li Xuan, Ren Lin, et al.
BMC Medicine|December 30, 2024
Intensified conditioning containing decitabine versus standard myeloablative conditioning for adult patients with KMT2A-rearranged leukemia: a multicenter retrospective studyZhongli Hu, Zinan Feng, Shiqi Liu, et al.
Annals of Hematology|March 25, 2022
Intestinal microbiota score could predict survival following allogeneic hematopoietic stem cell transplantationLijie Han, Haiyan Zhang, Ping Ma, et al.
Ebiomedicine|February 13, 2025
Dynamic forecasting module for chronic graft-versus-host disease progression based on a disease-associated subpopulation of B cells: a multicenter prospective studyYuanchen Ma, Jieying Chen, Zhiping Fan, et al.
Cancer|March 22, 2022
A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous system leukemiaXiaoxia Chen, Junwei Huang, Na Xu, et al.
American Journal of Hematology|January 2, 2023
Idarubicin plus BuCy versus BuCy conditioning regimens for intermediate-risk acute myeloid leukemia in first complete remission undergoing auto-HSCT: An open-label, multicenter, randomized phase 3 trialHui Liu, Fen Huang, Yu Zhang, et al.
Journal of Hematology & Oncology|March 8, 2022
Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trialKe Zhao, Ren Lin, Zhiping Fan, et al.
The Lancet Regional Health. Western Pacific|August 20, 2025
Decitabine combined with reduced-intensity conditioning for older patients with acute myeloid leukemia in composite complete remission undergoing allogeneic hematopoietic stem cell transplantation: a multicenter, single-arm, phase 2 trialQifa Liu, Zhongli Hu, Na Xu, et al.
The Lancet. Haematology|January 26, 2023
The effect of granulocyte-colony stimulating factor, decitabine, and busulfan-cyclophosphamide versus busulfan-cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trialLi Xuan, Min Dai, Erlie Jiang, et al.
Pageof 16

Showing results (121-130 of 152) with videos related to

Sort By:
Pageof 16
Journal of Translational Medicine|May 28, 2025
Efficacy and safety of third-generation CD19-CAR T cells incorporating CD28 and TLR2 intracellular domains for B-cell malignancies with central nervous system involvement: results of a pivotal trialBailin He, Ren Lin, Na Xu, et al.
Leukemia|November 18, 2020
A new pre-emptive TKIs strategy for preventing relapse based on BCR/ABL monitoring for Ph+ALL undergoing allo-HCT: a prospective clinical cohort studyHui Liu, Li Xuan, Ren Lin, et al.
BMC Medicine|December 30, 2024
Intensified conditioning containing decitabine versus standard myeloablative conditioning for adult patients with KMT2A-rearranged leukemia: a multicenter retrospective studyZhongli Hu, Zinan Feng, Shiqi Liu, et al.
Annals of Hematology|March 25, 2022
Intestinal microbiota score could predict survival following allogeneic hematopoietic stem cell transplantationLijie Han, Haiyan Zhang, Ping Ma, et al.
Ebiomedicine|February 13, 2025
Dynamic forecasting module for chronic graft-versus-host disease progression based on a disease-associated subpopulation of B cells: a multicenter prospective studyYuanchen Ma, Jieying Chen, Zhiping Fan, et al.
Cancer|March 22, 2022
A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous system leukemiaXiaoxia Chen, Junwei Huang, Na Xu, et al.
American Journal of Hematology|January 2, 2023
Idarubicin plus BuCy versus BuCy conditioning regimens for intermediate-risk acute myeloid leukemia in first complete remission undergoing auto-HSCT: An open-label, multicenter, randomized phase 3 trialHui Liu, Fen Huang, Yu Zhang, et al.
Journal of Hematology & Oncology|March 8, 2022
Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trialKe Zhao, Ren Lin, Zhiping Fan, et al.
The Lancet Regional Health. Western Pacific|August 20, 2025
Decitabine combined with reduced-intensity conditioning for older patients with acute myeloid leukemia in composite complete remission undergoing allogeneic hematopoietic stem cell transplantation: a multicenter, single-arm, phase 2 trialQifa Liu, Zhongli Hu, Na Xu, et al.
The Lancet. Haematology|January 26, 2023
The effect of granulocyte-colony stimulating factor, decitabine, and busulfan-cyclophosphamide versus busulfan-cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trialLi Xuan, Min Dai, Erlie Jiang, et al.
Pageof 16